These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1317199

  • 1. Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group.
    Jassem J, Karnicka-Młodkowska H, Drozd-Lula M, Strug A, Pilarska-Machowicz A, Michalski A, Kowal E, Moś-Antkowiak R, Zych J.
    Eur J Cancer; 1992; 28(2-3):473-6. PubMed ID: 1317199
    [Abstract] [Full Text] [Related]

  • 2. Epirubicin weekly in combination chemotherapy with cyclophosphamide and vincristine in untreated small cell lung cancer: a phase II trial.
    Kretzschmar A, Drings P.
    Onkologie; 1990 Apr; 13(2):141-2. PubMed ID: 2165228
    [Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer.
    Jassem J, Karnicka-Młodkowska H, Jassem E, Słupek A, Zych J, Wiatr E, Malak S, Moś-Antkowiak R, Szymaczek-Meyer L, Pilarska-Machowicz A.
    Lung Cancer; 1994 Sep; 11(3-4):283-91. PubMed ID: 7812705
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 5. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Horiguchi T, Kodani T, Maeda T, Tabata M, Shibayama T.
    Cancer; 1993 Sep 01; 72(5):1597-601. PubMed ID: 8394202
    [Abstract] [Full Text] [Related]

  • 6. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients.
    Hirsch FR, Osterlind K, Jeppesen N, Dombernowsky P, Ingeberg S, Sorensen PG, Kristensen C, Hansen HH.
    Ann Oncol; 2001 May 01; 12(5):647-53. PubMed ID: 11432623
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study.
    Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, Trovò MG, Nascimben O, Sibau A, Talamini R.
    Eur J Cancer; 1994 May 01; 30A(10):1474-8. PubMed ID: 7833105
    [Abstract] [Full Text] [Related]

  • 8. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, Luedke D, Hurtubise M, Lanzotti V, Goodlow J.
    J Clin Oncol; 1989 Apr 01; 7(4):450-6. PubMed ID: 2538577
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 10. [EPICO in the treatment of small cell bronchial cancer. 3. Intermediate analysis].
    Drings P, Bülzebruck H, Hruska D, Manke HG, Schuler G.
    Onkologie; 1986 Aug 15; 9 Suppl 1():14-20. PubMed ID: 3018648
    [Abstract] [Full Text] [Related]

  • 11. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM.
    J Clin Oncol; 1990 Jan 15; 8(1):39-47. PubMed ID: 2153194
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide.
    Casadio M, Lelli G, Giordani S, Boltri B, Blotta A, Busutti L, Ramini R, Falcone F, Pannuti F.
    J Chemother; 1990 Jun 15; 2(3):199-202. PubMed ID: 2166145
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer.
    Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S, Intini C.
    J Chemother; 1993 Oct 15; 5(5):344-7. PubMed ID: 8106908
    [Abstract] [Full Text] [Related]

  • 15. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 15; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 16. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 15; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 17. Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?
    Jereczek-Fossa B, Jassem J, Karnicka-Młodkowska H, Badzio A, Moś-Antkowaik R, Krawczyk K, Kowal E, Pilarska-Machowicz A, Radzikowska E, Malak K.
    J Cancer Res Clin Oncol; 1998 May 15; 124(2):106-12. PubMed ID: 9654193
    [Abstract] [Full Text] [Related]

  • 18. Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer.
    Macchiarini P, Chella A, Riva A, Mengozzi G, Silvano G, Solfanelli S, Angeletti CA.
    Am J Clin Oncol; 1990 Dec 15; 13(6):495-500. PubMed ID: 2173392
    [Abstract] [Full Text] [Related]

  • 19. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L.
    Cancer; 1993 Aug 01; 72(3):697-706. PubMed ID: 8392903
    [Abstract] [Full Text] [Related]

  • 20. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G, Spielmann M, Dieras V, Tubiana-Hulin M, Bonneterre J, Pouillart P, Kayitalire L, Guastalla JP, Graffand N, Garet F, Dumortier A, Pellae-Cosset B.
    Semin Oncol; 1997 Feb 01; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.